The name determines the pathway of care
For generations, a condition affecting one in eight women worldwide was named for what it appeared to be rather than what it truly was — and that mismatch between name and reality quietly shaped how medicine failed millions of patients. Through an unprecedented global consensus uniting 56 organizations and over 14,000 voices, the medical community has chosen a new name: one that honors the metabolic and endocrine truth of the syndrome rather than its most visible and misleading symptom. The renaming of PCOS to POMS is not merely administrative — it is an act of epistemic correction, a recognition that language is never neutral when it touches the body.
- For decades, the word 'cyst' sent women to the wrong specialists and the wrong treatments, while the real metabolic crisis unfolded unaddressed beneath the surface.
- The outdated terminology carried stigma that made patients feel fundamentally broken, compounding misdiagnosis with a burden of shame that had no clinical basis.
- An extraordinary global mobilization — 56 organizations, 14,360 participants across generations and disciplines — built the consensus needed to dismantle a name that had outlived its usefulness.
- Eighty-two percent of respondents endorsed a name centered on metabolic and endocrine dysfunction, stripping the misleading focus on ovaries and cysts from the official diagnosis.
- A three-year transition is now underway, threading the new nomenclature through medical schools, journals, insurance codes, and the lived vocabularies of millions of patients worldwide.
Una de cada ocho mujeres en el planeta padece una condición que, durante décadas, fue nombrada por lo que parecía ser y no por lo que realmente es. El síndrome de ovario poliquístico orientaba a médicos y pacientes hacia los ovarios, hacia los quistes, hacia un problema ginecológico. Pero la ciencia había avanzado: la condición nunca fue verdaderamente sobre los quistes, sino sobre una disfunción endocrina y metabólica que afecta a casi todos los sistemas del cuerpo. El nombre antiguo se había convertido en un obstáculo.
Bajo el liderazgo de Helena J. Teede, del Monash Centre for Health Research and Implementation en Melbourne, se inició un proceso inusual: una conversación global sobre cómo nombrar aquello que daña a millones de mujeres. Participaron 56 organizaciones y más de catorce mil personas —pacientes, médicos, enfermeras, endocrinólogos, investigadores— de todas las regiones del mundo, desde adolescentes de diez años hasta adultos mayores. Se realizaron encuestas, talleres y revisiones exhaustivas de la literatura científica, utilizando métodos Delphi modificados para construir consenso entre culturas y disciplinas.
El resultado fue contundente: el 82% de los participantes respaldó un nombre que describiera lo que el síndrome realmente hace. La palabra 'quiste' debía desaparecer —era engañosa y cargaba estigma. En su lugar surgió el síndrome de ovario metabólico y poliendocrino, POMS en inglés, SOMP en español, un nombre que coloca la disfunción metabólica y endocrina en el centro del diagnóstico.
Los nombres importan porque moldean el pensamiento médico y la comprensión que los pacientes tienen de sí mismos. La terminología antigua había contribuido a diagnósticos erróneos y atención tardía: mujeres con ciclos irregulares eran derivadas a ginecólogos cuando necesitaban endocrinólogos. El nuevo nombre refleja lo que la ciencia comprende hoy: un trastorno que altera el procesamiento de glucosa y grasa, que eleva el riesgo de diabetes y enfermedades cardíacas, y que exige una respuesta multidisciplinaria.
La transición tomará tres años. Las facultades de medicina actualizarán sus planes de estudio, las revistas científicas cambiarán su lenguaje y los sistemas de salud ajustarán sus códigos. Es un cambio lento, pero deliberado, diseñado para reducir el estigma, mejorar el diagnóstico y ofrecer a millones de mujeres un camino más claro hacia la comprensión y el manejo de su salud.
A condition that affects one in every eight women on the planet has been given a new name. For decades, it was called polycystic ovary syndrome—a term that pointed doctors and patients toward the ovaries, toward cysts, toward a gynecological problem. But the science had moved on. The condition was never really about the cysts at all. It was about hormones gone awry, about metabolism struggling, about a cascade of endocrine dysfunction that touched nearly every system in the body. The old name was getting in the way.
This realization led to an unusual process: a global conversation about what to call the thing that was harming millions of women. Led by Helena J. Teede, a researcher at Monash Centre for Health Research and Implementation in Melbourne, an international team set out to rename the syndrome through structured consensus. They wanted the name to match what the disease actually was.
The effort was comprehensive. Fifty-six major organizations participated. More than fourteen thousand people—patients, doctors, nurses, endocrinologists, gynecologists, researchers—from every region of the world weighed in. Adolescents as young as ten sat alongside adults in their sixties. The team conducted surveys, held workshops, reviewed the scientific literature exhaustively, and used modified Delphi methods to build agreement across cultures and disciplines.
What emerged was striking in its clarity. Eighty-two percent of respondents supported a name that would actually describe what the syndrome does—one that captured its multisystem nature, its endocrine roots, its metabolic consequences. The word "cyst" had to go. It was misleading and it carried stigma. In its place came "polycystic ovary metabolic and polyendocrine syndrome"—or POMS in English, SOMP in Spanish. The new name centered metabolism and endocrine dysfunction, not the ovaries.
Why does a name matter? Because names shape how doctors think. They shape how patients understand themselves. The old terminology had contributed to misdiagnosis and delayed care. Women came in complaining of irregular periods or infertility and were sent to gynecologists when they needed endocrinologists. The condition was treated as a reproductive problem when it was fundamentally a metabolic one. The stigma attached to the word "syndrome" and the image of "cysts" made patients feel broken in a particular way—as though their bodies were defective machines. A better name could change that conversation.
The new nomenclature reflects what researchers now understand: that the disorder involves dysfunction across multiple hormone systems, that it disrupts how the body processes glucose and fat, that it increases risk for diabetes and heart disease, that it is not simply a women's health issue but a metabolic crisis that demands a multidisciplinary response. The change also signals something cultural—a recognition that naming matters, that precision in language improves care, that the people living with a condition deserve to have it called by its true name.
The transition will take three years. Medical schools will update their curricula. Journals will shift their language. Insurance systems will adjust their codes. Patients will learn a new term for something they have lived with for years. It is a slow change, but it is a deliberate one, designed to reduce stigma, improve diagnosis, and ultimately give millions of women a clearer path to understanding and managing their health.
Notable Quotes
The redenomination represents a significant advance in capturing the true pathophysiology of the syndrome, helping improve understanding and clinical management globally.— International consensus study findings
The Hearth Conversation Another angle on the story
Why did it take so long for medicine to realize the name was wrong?
Because the condition was first described by its most visible feature—the cysts on the ovaries. That's what you could see on ultrasound. But seeing something doesn't mean you understand it. As endocrinology advanced, researchers realized the cysts were almost a side effect of the real problem: hormonal chaos.
And the old name actually made things worse?
Significantly. Women would go to gynecologists expecting ovarian surgery or fertility treatment, when what they really needed was metabolic management. The name pointed everyone in the wrong direction. It also made patients feel like their bodies were cosmetically broken rather than metabolically dysregulated.
Fourteen thousand people in the consensus process—that's a lot of voices. Did they all agree?
Not unanimously, but overwhelmingly. Eighty-two percent supported a name that captured the multisystem nature. That's remarkable agreement across cultures and professions. Patients and doctors were aligned on this.
What changes practically when the name changes?
Everything downstream. How it's taught in medical school. How insurance codes it. How research is funded. How women talk about their own diagnosis. A better name opens the door to better care.
Is this just semantics, or does it actually affect outcomes?
It's not semantics. Language shapes clinical thinking. If you call something a gynecological problem, you treat it gynecologically. If you call it metabolic, you screen for diabetes, you manage insulin resistance, you think about cardiovascular risk. The name determines the pathway.
Three years to transition—why so long?
Because you can't flip a switch on medical practice. Training programs need time to change. Journals need to update. Patients need to learn. But three years is also a commitment—it says this isn't a casual rebrand, it's a fundamental shift in how we understand the condition.